I'll value ONC-201 step by step. Let me start by gathering all the necessary inputs.
{
"asset_id": "ONC-201",
"name": "DLL3 T-cell engager (ES-SCLC)",
"therapeutic_area": "oncology",
"indication": "Extensive-stage small cell lung cancer (2L+)",
"modality": "T-cell engager (bispecific)",
"current_phase": "PHASE2",
"peak_sales_usd_m": 1600,
"years_to_launch": 4,
"remaining_rd_cost_by_phase": {
"PHASE2": 70,
"PHASE3": 300,
"FILED": 25
},
"launch_to_loe_years": 11,
"discount_rate": 0.12,
"net_margin": 0.55,
"notes": "Crowded DLL3 space; incumbent already Phase 3. Strong single-arm Ph2 ORR signal supports a competitive peak. Thin rNPV given oncology PoS -> structure matters."
}{
"discount_rate_conventions": {
"large_pharma": "8-10%",
"established_biotech": "10-12%",
"early_clinical_private_biotech": "12-15%",
"preclinical_or_platform": "15-20%+",
"note": "Higher risk / earlier stage / private -> higher discount rate. The PoS already captures technical/regulatory risk, so the discount rate should reflect time value + systematic risk, NOT be double-counted with PoS."
},
"rnpv_model": {
"method": "Simplified peak-sales rNPV.",
"steps": [
"1. Cumulative PoS = product of remaining phase transitions (incl. NDA/BLA->approval) for the asset's current phase and therapeutic area.",
"2. Peak commercial value = peak_sales * net_margin * REVENUE_YEARS_FACTOR, where REVENUE_YEARS_FACTOR approximates the sum of the on-market cash-flow stream as a multiple of one peak year (ramp up, plateau, decline to LoE).",
"3. Discount the commercial value from the revenue mid-point (years_to_launch + REVENUE_MIDPOINT_OFFSET) to present at the discount rate.",
"4. Risk-adjust the discounted commercial value by the cumulative PoS.",
"5. Subtract risk-adjusted, discounted remaining R&D (each phase's spend discounted from its spend year and weighted by the PoS of having reached that phase \u2014 here we conservatively expense remaining R&D at full probability since the buyer pays it).",
"6. rNPV = risk-adjusted discounted commercial value - discounted remaining R&D."
],
"REVENUE_YEARS_FACTOR": 6.5,
"REVENUE_MIDPOINT_OFFSET": 2.0,
"note": "REVENUE_YEARS_FACTOR=6.5 means the lifetime on-market cash-flow stream (already net-of-margin) is modelled as ~6.5x a single peak year \u2014 a standard simplification for an ~10-13yr exclusivity window with ramp/plateau/decline, where the discounted stream is worth several peak years rather than the full undiscounted count. REVENUE_MIDPOINT_OFFSET=2 places the single discounting anchor ~2 years after launch (an early-plateau centre of mass for the discounted stream). These are deliberately transparent simplifications of a full year-by-year DCF; a real model would discount each revenue year separately."
},
"deal_structure_conventions": {
"upfront_as_pct_of_rnpv": "Upfront typically 15-30% of asset rNPV at Ph2; lower (~5-15%) earlier, higher (~30-45%) at Ph3/filed.",
"biobucket": "Total milestones+royalties (the 'biobucket') is benchmarked to comparable deals in the same area/phase and usually several multiples of the upfront.",
"royalty": "Tiered royalty on net sales, typically high-single-digit to mid-teens for clinical-stage oncology/specialty assets."
}
}Now let me get the PoS data for oncology at Phase 2 and comparable oncology deals.
{
"area": "oncology",
"label": "Oncology (solid + heme malignancy, ex-hematology benign)",
"transitions": {
"P1->P2": 0.629,
"P2->P3": 0.241,
"P3->REG": 0.477,
"REG->APP": 0.935
},
"source": "BIO/Informa/QLS 2011-2020 oncology; Phase-1-to-approval LoA 5.3%. Wong-Siah-Lo (2019) report oncology LoA ~3.4% on an earlier window.",
"phase": "PHASE2",
"remaining_transitions": [
"P2->P3",
"P3->REG",
"REG->APP"
],
"cumulative_pos": 0.1075
}{
"count": 3,
"deals": [
{
"deal": "DLL3 bispecific (oncology, Ph2)",
"area": "oncology",
"phase_at_deal": "PHASE2",
"upfront_usd_m": 175,
"biobucket_usd_m": 1300,
"royalty_pct": "10-15%",
"year": 2023
},
{
"deal": "Solid-tumor ADC (oncology, Ph1/2)",
"area": "oncology",
"phase_at_deal": "PHASE1",
"upfront_usd_m": 60,
"biobucket_usd_m": 1000,
"royalty_pct": "high single digit-12%",
"year": 2023
},
{
"deal": "Late-stage oncology asset (Ph3)",
"area": "oncology",
"phase_at_deal": "PHASE3",
"upfront_usd_m": 400,
"biobucket_usd_m": 1500,
"royalty_pct": "12-18%",
"year": 2022
}
],
"note": "Upfront/biobucket in $M; later-stage deals carry a larger upfront share."
}I now have everything needed. Let me work through the valuation.
ONC-201 is a Phase 2 oncology asset. Remaining transitions to approval:
| Transition | Probability |
|---|---|
| P2 → P3 | 0.241 |
| P3 → REG | 0.477 |
| REG → APP | 0.935 |
Cumulative PoS = 0.241 × 0.477 × 0.935 ≈ 10.75%
This is the key risk driver — a typical "Phase 2 oncology" survival rate, and it dominates the valuation.
Step 1 — Peak commercial value (lifetime, net-of-margin):
- Peak sales = $1,600M
- Net margin = 0.55
- Revenue-years factor = 6.5
- Commercial value = 1,600 × 0.55 × 6.5 = $5,720M
Step 2 — Discount to present:
- Discounting anchor = years_to_launch (4) + midpoint offset (2) = 6 years
- Discount factor = 1 / (1.12)^6 = 1 / 1.9738 = 0.5066
- Discounted commercial value = 5,720 × 0.5066 = $2,897.8M
Step 3 — Risk-adjust by PoS:
- 2,897.8 × 0.1075 = $311.5M
Step 4 — Remaining R&D (discounted, expensed at full probability per convention):
| Phase | Spend | Spend year | Discount factor (1.12^–t) | PV |
|---|---|---|---|---|
| Phase 2 | $70M | ~now (yr 0) | 1.000 | $70.0M |
| Phase 3 | $300M | ~yr 2 | 0.7972 | $239.2M |
| Filed | $25M | ~yr 4 | 0.6355 | $15.9M |
| Total | $325.1M |
(R&D timing aligned to the 4-year path to launch: Ph2 now, Ph3 mid-program, filing near launch.)
Step 5 — rNPV:
$$rNPV = 311.5 - 325.1 = \boxed{-\$13.6M}$$
This matches the note in the asset file ("thin rNPV given oncology PoS → structure matters"). The unrisked discounted commercial value is ~$2.9B, but the 10.75% PoS plus full R&D burden compresses it to roughly zero. Crucially, the buyer pays the R&D regardless — so the risk-adjusted commercial value of $311.5M is what a deal should be benchmarked against, not the net rNPV.
Given the economics, this should be a back-end-loaded deal — modest upfront, large milestone biobucket that pays out only as risk retires.
Benchmark anchor: The closest comparable is the 2023 DLL3 bispecific at Ph2 (same modality, same target, same phase): $175M upfront / $1,300M biobucket / 10–15% royalty. That deal frames market expectations directly.
Calibration against our numbers:
- Convention: Ph2 upfront = 15–30% of rNPV. But net rNPV here is ~$0, so anchoring to rNPV alone breaks down. The market clearly prices off the risk-adjusted commercial value (~$311M) and strategic value, not net rNPV.
- A defensible upfront is ~15–20% of the risk-adjusted commercial value → ~$47–62M intrinsically, but the comparable DLL3 deal ($175M) is richer, reflecting competitive/strategic premium for the target class.
| Component | Recommendation | Rationale |
|---|---|---|
| Upfront | $100–130M | Below the $175M comp — justified because we're a follower in a crowded DLL3 space (incumbent already Ph3) and net rNPV is break-even. Discounted from the comp to reflect competitive risk. |
| Biobucket (total milestones) | $1,100–1,300M | In line with the DLL3 comp. Heavily back-end loaded: skew toward Ph3 success, approval, and sales milestones so the seller captures upside only if the asset clears its 10.75% PoS gauntlet. |
| — Development/regulatory milestones | ~$400–500M | Tied to Ph3 start, Ph3 readout, approval. |
| — Sales milestones | ~$700–800M | Tied to $250M/$500M/$1B/$1.5B net-sales thresholds. |
| Royalty | Tiered 10–14% on net sales | Matches the DLL3 comp's 10–15% band; lower tier early, escalating with volume. |
Bottom line: License with ~$100–130M upfront, ~$1.2B biobucket weighted to Ph3/approval/sales, and a 10–14% tiered royalty — a structure that keeps capital-at-risk low against a break-even rNPV while paying generously only if the asset survives its oncology odds.
I now have everything needed. Let me work through the valuation.
ONC-201 is a Phase 2 oncology asset. Remaining transitions to approval:
| Transition | Probability |
|---|---|
| P2 → P3 | 0.241 |
| P3 → REG | 0.477 |
| REG → APP | 0.935 |
Cumulative PoS = 0.241 × 0.477 × 0.935 ≈ 10.75%
This is the key risk driver — a typical "Phase 2 oncology" survival rate, and it dominates the valuation.
Step 1 — Peak commercial value (lifetime, net-of-margin):
- Peak sales = $1,600M
- Net margin = 0.55
- Revenue-years factor = 6.5
- Commercial value = 1,600 × 0.55 × 6.5 = $5,720M
Step 2 — Discount to present:
- Discounting anchor = years_to_launch (4) + midpoint offset (2) = 6 years
- Discount factor = 1 / (1.12)^6 = 1 / 1.9738 = 0.5066
- Discounted commercial value = 5,720 × 0.5066 = $2,897.8M
Step 3 — Risk-adjust by PoS:
- 2,897.8 × 0.1075 = $311.5M
Step 4 — Remaining R&D (discounted, expensed at full probability per convention):
| Phase | Spend | Spend year | Discount factor (1.12^–t) | PV |
|---|---|---|---|---|
| Phase 2 | $70M | ~now (yr 0) | 1.000 | $70.0M |
| Phase 3 | $300M | ~yr 2 | 0.7972 | $239.2M |
| Filed | $25M | ~yr 4 | 0.6355 | $15.9M |
| Total | $325.1M |
(R&D timing aligned to the 4-year path to launch: Ph2 now, Ph3 mid-program, filing near launch.)
Step 5 — rNPV:
$$rNPV = 311.5 - 325.1 = \boxed{-\$13.6M}$$
This matches the note in the asset file ("thin rNPV given oncology PoS → structure matters"). The unrisked discounted commercial value is ~$2.9B, but the 10.75% PoS plus full R&D burden compresses it to roughly zero. Crucially, the buyer pays the R&D regardless — so the risk-adjusted commercial value of $311.5M is what a deal should be benchmarked against, not the net rNPV.
Given the economics, this should be a back-end-loaded deal — modest upfront, large milestone biobucket that pays out only as risk retires.
Benchmark anchor: The closest comparable is the 2023 DLL3 bispecific at Ph2 (same modality, same target, same phase): $175M upfront / $1,300M biobucket / 10–15% royalty. That deal frames market expectations directly.
Calibration against our numbers:
- Convention: Ph2 upfront = 15–30% of rNPV. But net rNPV here is ~$0, so anchoring to rNPV alone breaks down. The market clearly prices off the risk-adjusted commercial value (~$311M) and strategic value, not net rNPV.
- A defensible upfront is ~15–20% of the risk-adjusted commercial value → ~$47–62M intrinsically, but the comparable DLL3 deal ($175M) is richer, reflecting competitive/strategic premium for the target class.
| Component | Recommendation | Rationale |
|---|---|---|
| Upfront | $100–130M | Below the $175M comp — justified because we're a follower in a crowded DLL3 space (incumbent already Ph3) and net rNPV is break-even. Discounted from the comp to reflect competitive risk. |
| Biobucket (total milestones) | $1,100–1,300M | In line with the DLL3 comp. Heavily back-end loaded: skew toward Ph3 success, approval, and sales milestones so the seller captures upside only if the asset clears its 10.75% PoS gauntlet. |
| — Development/regulatory milestones | ~$400–500M | Tied to Ph3 start, Ph3 readout, approval. |
| — Sales milestones | ~$700–800M | Tied to $250M/$500M/$1B/$1.5B net-sales thresholds. |
| Royalty | Tiered 10–14% on net sales | Matches the DLL3 comp's 10–15% band; lower tier early, escalating with volume. |
Bottom line: License with ~$100–130M upfront, ~$1.2B biobucket weighted to Ph3/approval/sales, and a 10–14% tiered royalty — a structure that keeps capital-at-risk low against a break-even rNPV while paying generously only if the asset survives its oncology odds.
Deterministic simplified peak-sales rNPV (model in data.ASSUMPTIONS['rnpv_model']). PoS from BIO/Informa/QLS 2011-2020 & Wong-Siah-Lo (2019). A strong agent should recover the cumulative PoS, a discounted risk-adjusted value in this ballpark, net out remaining R&D, and propose a deal range benchmarked to the comparables — using only the returned inputs (no fabricated peak-sales or PoS numbers).
| Step | Value | Detail / formula |
|---|---|---|
| Asset | ONC-201 | DLL3 T-cell engager (ES-SCLC) — PHASE2, Oncology (solid + heme malignancy, ex-hematology benign) |
| Cumulative PoS to approval | 10.7% | P2->P3=0.241 x P3->REG=0.477 x REG->APP=0.935 = 0.1075 |
| Unrisked commercial value | $5720M | peak $1600M x margin 0.55 x revenue-years 6.5 |
| Discounting | /(1+0.12)^6 = 0.507 | launch in 4y + midpoint offset 2.0 |
| Risk-adj. discounted commercial value | $311M | commercial $5720M x disc 0.507 x PoS 0.1075 |
| Remaining R&D (PV) | $298M | by phase: {'PHASE2': 62.5, 'PHASE3': 213.5, 'FILED': 22.3} |
| rNPV | $13M | risk-adj discounted commercial value − R&D PV |
| Suggested upfront | $2M – $4M | 15–30% of rNPV (PHASE2 band) |
| Suggested total biobucket | $18M – $37M | ~9.3x upfront, from 3 oncology comps |
| Structure note | rNPV thin/negative at base assumptions: keep upfront minimal and shift value to back-loaded development/approval & sales milestones (risk-sharing). |